Identifying Potential Biomarkers for Qualification and Describing Contexts of Use To Address Areas Important to Drug Development; Request for Comments, 8089-8091 [2015-02976]
Download as PDF
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 30 / Friday, February 13, 2015 / Notices
opioid antagonist with high affinity for
the mu opioid receptor. The naloxone is
intended to be inactive when
SUBOXONE is used appropriately, but
to precipitate more severe withdrawal
symptoms if the product is crushed and
injected by an individual dependent on
full opioid agonists. A variety of factors
such as degree of opioid dependence,
relative amount of buprenorphine
exposure, and route of administration
influence the antagonist effect of
naloxone. As a result, buprenorphine/
naloxone combination products may not
have the same effect on non-dependent
opioid abusers or abusers of
buprenorphine. As stated in the
approved SUBOXONE labeling in
section 12.2, ‘‘naloxone in
buprenorphine/naloxone tablets may
deter injection of buprenorphine/
naloxone tablets by persons with active
substantial heroin or other full muopioid dependence,’’ but ‘‘some opioiddependent persons, particularly those
with a low level of full mu-opioid
physical dependence or those whose
opioid physical dependence is
predominantly to buprenorphine, abuse
buprenorphine/naloxone combinations
by the intravenous or intranasal route.’’
SUBUTEX has important therapeutic
benefits for certain patient populations
that may not tolerate or should not be
exposed to the naloxone in SUBOXONE.
Specifically, as explained in section
5.11 of the approved labeling for
SUBOXONE, ‘‘[b]uprenorphine/
naloxone products are not
recommended in patients with severe
hepatic [liver] impairment and may not
be appropriate for patients with
moderate hepatic impairment.’’ Section
5.11 further states that ‘‘hepatic
impairment results in a reduced
clearance of naloxone to a much greater
extent than buprenorphine,’’ and thus,
‘‘patients with severe hepatic
impairment will be exposed to
substantially higher levels of naloxone
than patients with normal hepatic
function.’’ SUBUTEX also is preferred to
SUBOXONE for patients transitioning
from treatment with methadone or other
long-acting opioid products because
they are at higher risk for precipitated
and prolonged withdrawal, and the
naloxone in buprenorphine/naloxone
combination products may cause worse
withdrawal in this population.
Although Reckitt has publicly stated
that SUBUTEX ‘‘creates a greater risk of
misuse, abuse, and diversion’’ than
SUBOXONE (please refer to letter from
Reckitt to Health Care Providers,
available at https://
buprenorphine.samhsa.gov/
SubutexDiscontinuation9-16-11.pdf),
Reckitt has not submitted any data,
VerDate Sep<11>2014
21:56 Feb 12, 2015
Jkt 235001
information, or analysis to support this
claim. Based on our independent review
of the available data and the published
studies on the relative abuse liability of
SUBUTEX and SUBOXONE, we do not
have sufficient information at this time
to determine that SUBUTEX poses an
increased potential for abuse or misuse
relative to SUBOXONE. Furthermore, as
discussed previously, SUBUTEX has
important therapeutic benefits for
certain patient populations that may not
tolerate or should not be exposed to the
naloxone in SUBOXONE.
For these reasons, based on the data
and information available to the Agency
at this time, we find that the benefits of
SUBUTEX continue to outweigh the
risks. Therefore, we conclude that
SUBUTEX was not withdrawn from sale
for reasons of safety or effectiveness.
Accordingly, the Agency will
continue to list SUBUTEX in the
‘‘Discontinued Drug Product List’’
section of the Orange Book. The
‘‘Discontinued Drug Product List’’
delineates, among other items, drug
products that have been discontinued
from marketing for reasons other than
safety or effectiveness. FDA will not
begin procedures to withdraw approval
of ANDAs that refer to SUBUTEX. Such
ANDAs may continue to be approved by
the Agency as long as they meet all
other legal and regulatory requirements
for the approval of ANDAs.
Dated: February 9, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–03001 Filed 2–12–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–2187]
Identifying Potential Biomarkers for
Qualification and Describing Contexts
of Use To Address Areas Important to
Drug Development; Request for
Comments
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; request for comments.
The Food and Drug
Administration (FDA or Agency) is
seeking information to facilitate
development and qualification of
biomarkers in areas related to human
drug therapeutics. Towards this goal,
FDA is encouraging interested groups
and individuals to submit information
on specific medical and biological areas
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
8089
where novel biomarkers can be
identified that would meaningfully
advance drug development. FDA
encourages respondents to describe
evidentiary considerations that are
important to qualify these biomarkers
for a specific context of use. Details of
information that should be provided to
the Agency are described in the survey.
DATES: Submit either electronic or
written comments by April 14, 2015.
ADDRESSES: You may submit comments
by any of the following methods:
Electronic Submissions
Submit electronic comments in either
of the following ways:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• SurveyMonkey Link: https://
www.surveymonkey.com/s/RHJLHS7.
This survey may be used to provide
feedback on answers to questions
regarding potential biomarkers for
qualification and to describe contexts of
use to address areas important to drug
development.
Written Submissions
Submit written submissions in the
following ways:
• Mail/Hand delivery/Courier (for
paper submissions): Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Instructions: All submissions received
must include the Docket No. FDA–
2014–N–2187 for this document. All
comments received may be posted
without change to https://
www.regulations.gov, including any
personal information provided. It is
only necessary to send one set of
comments. For additional information
on submitting comments, see the
‘‘Request for Information’’ heading of
the SUPPLEMENTARY INFORMATION section
of this document.
Docket: For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, between 9
a.m. and 4 p.m., Monday through
Friday.
FOR FURTHER INFORMATION CONTACT:
Marianne Noone, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 21, Rm. 4528, Silver Spring,
MD 20993–0002, 301–796–7495.
E:\FR\FM\13FEN1.SGM
13FEN1
8090
Federal Register / Vol. 80, No. 30 / Friday, February 13, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
I. Background
The President signed into law the
Food and Drug Administration Safety
and Innovation Act (FDASIA) (Pub. L.
112–144) on July 9, 2012. Title I of
FDASIA reauthorizes the Prescription
Drug User Fee Act (PDUFA) and
provides FDA with the user fee
resources necessary to maintain an
efficient review process for human drug
and biological products. The
reauthorization of PDUFA added
performance goals and procedures for
the Agency that represent FDA’s
commitments during fiscal years 2013
through 2017. These commitments are
fully described in the document entitled
‘‘PDUFA Reauthorization Performance
Goals and Procedures Fiscal Years 2013
through 2017’’ (PDUFA Goals Letter),
available on FDA’s Web site at https://
www.fda.gov/downloads/ForIndustry/
UserFees/PrescriptionDrugUserFee/
UCM270412.pdf. Section IX of the
PDUFA Goals Letter entitled
‘‘Enhancing Regulatory Science and
Expediting Drug Development’’
references support for the identification
and advancement of biomarkers.
A biomarker is an objective
characteristic that is measured and
evaluated as an indicator of normal
biologic processes, pathogenic
processes, or pharmacologic responses
to treatment. Biomarkers can serve
many purposes in clinical drug
development, including the following:
Defining the appropriate patient
populations for study, as well as those
who should receive the drug in clinical
practice; pharmacodynamic markers for
proof of concept and dose selection; and
pharmacodynamic markers of adverse
effects. A subset of pharmacodynamic
biomarkers can serve as replacements
for clinical efficacy endpoints that
reflect how a patient feels, functions, or
survives. The path to development of
promising therapeutics can be enabled
by the availability of biomarkers that are
analytically validated and clinically
qualified for a specific context of use
(i.e., a comprehensive, clear, and precise
statement that describes the manner of
use, interpretation, and purpose of use
of a biomarker in drug development).
Qualification is based on a body of
evidence that demonstrates that the
biomarkers are fit for purpose in drug
development and evaluation (https://
www.fda.gov/Drugs/
DevelopmentApprovalProcess/Drug
DevelopmentToolsQualification
Program/ucm284076.htm). Further,
qualification is dependent on the
specific proposed context of use.
Biomarkers that are qualified can help
VerDate Sep<11>2014
21:56 Feb 12, 2015
Jkt 235001
A. Information Requirements
In general, submitted information
should include the following for each
biomarker nominated, as well as any
other relevant information:
• Areas that have a critical need for
biomarkers to assist drug development;
• The name of the biomarker;
• The proposed context of use for the
biomarker (if known);
• The reason why the biomarker
should be considered, taking into
account its usefulness as a drug
development tool; and
• Any evidence that should be
developed to support qualification of
the biomarker.
d. Are there areas that appear to be
promising for the development of new
biomarkers and for which collaborative
engagement from stakeholders offers a
path forward? If so, please explain.
• Are there groups positioned to
accomplish this? If yes, please describe.
e. Are there barriers that preclude
engagement or investment in biomarkers
for these priority areas? If yes, please
explain.
2. In each of these priority areas that
are important to drug development,
please provide the following
information:
a. Biomarker: What specific
biomarkers do you believe represent the
greatest near-term opportunity to
establish utility in drug development
(i.e., that could be substantially
advanced by facilitating discussion and
consensus building)?
b. Rationale: Why should the
biomarker(s) be included on the list,
taking into account its usefulness in
regulatory decisionmaking as a drug
development tool?
c. Context of use: Can you please
describe/propose a specific context of
use for the biomarker(s)?
d. Evidentiary gaps: To support the
proposed context of use, what do you
see as the largest evidentiary gaps that
need to be addressed to permit ‘‘fit for
purpose’’ qualification?
e. How can these evidentiary gaps be
addressed?
f. Collaborative data sharing: Can any
of these gaps be addressed by
collaborative data sharing of existing
data versus prospective studies
specifically dedicated to addressing the
gap?
3. Please indicate your affiliation from
the following list: Academia,
pharmaceutical sector, biotechnology
sector, government, professional
organization, non-profit organization,
clinician, patient advocacy group,
patient, or other (please provide
specifics, if you choose other).
B. Questions and Requests
Specific questions and requests are as
follows:
1. Are there specific aspects of drug
development that could be enhanced
through the development of biomarkers?
a. Please list the specific applications
of biomarkers that address areas
important to drug development.
b. Please list the specific areas (for
example, a specific disease area or an
organ toxicity) needed for development
of biomarkers important to drug
development.
c. Is there information or efforts
which could be leveraged to advance
these areas? If yes, please describe.
III. Paperwork Reduction Act
This Federal Register notice requests
input from biomarker experts from
academia, the pharmaceutical industry,
and government organizations on the
evidentiary standards for biomarkers or
on the expectations about data for
qualification of different types of
biomarkers.
This request is exempt from the Office
of Management and Budget’s review
under 5 CFR 1320.3(h)(4): Facts or
opinions submitted in response to
general solicitations of comments from
the public, published in the Federal
Register or other publications,
regardless of the form or format thereof,
to progressively reduce uncertainty
about the outcome of clinical
development programs.
Public/private partnerships involving
regulatory, academic, and industry
scientists, collaborating within a
precompetitive framework, are essential
to catalyzing progress. Because of
limitations in resources, such efforts
must be focused on the opportunities
that offer the greatest potential for
impact.
FDA intends to facilitate
identification of the most promising
biomarkers and the areas important to
drug development and to promote
efforts that will aid in the qualification
and regulatory adoption of the drug
development framework.
II. Request for Information
FDA is seeking public feedback to
identify promising biomarker
candidates in areas important to drug
development and to identify
considerations for evidence needed to
qualify various types of biomarkers for
specific contexts of use. FDA requests
identification of specific biomarkers
with a proposed context of use and of
the type of evidence needed to support
qualification. After reviewing the
information provided, FDA will post the
collated information on its Web site.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
E:\FR\FM\13FEN1.SGM
13FEN1
Federal Register / Vol. 80, No. 30 / Friday, February 13, 2015 / Notices
provided that no person is required to
supply specific information pertaining
to the commenter, other than that
necessary for self-identification, as a
condition of the Agency’s full
consideration of the comment.
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1049]
Conditional Approval of New Animal
Drugs; Public Meeting; Request for
Comments
Food and Drug Administration,
HHS.
Notification of public meeting;
request for comments.
tkelley on DSK3SPTVN1PROD with NOTICES
ACTION:
The Food and Drug Administration
(FDA) is announcing a public meeting to
explore the use of statutory changes to
expand the use of conditional approval
to additional categories of new animal
drugs. This policy exploration is
consistent with a stated performance
goal in the Animal Drug User Fee
Amendments of 2013 (ADUFA III) goals
letter. FDA is requesting that you submit
any comments related to this issue by
September 30, 2015.
Date and Time: The public meeting
will be held on March 16, 2015, from 1
p.m. until 4 p.m.
Location: The public meeting will be
held at the Center for Veterinary
Medicine, Food and Drug
Administration, 7519 Standish Pl., 3rd
Floor, Rockville, MD 20855. Parking is
free.
Contact Person: Laura Bradbard,
Center for Veterinary Medicine, Food
and Drug Administration, 7519 Standish
Pl., Rm. 159, Rockville, MD 20855, 240–
276–9109, FAX: 240–276–9020, email:
Laura.Bradbard@fda.hhs.gov.
Registration: Registration is free and
available on a first-come, first-served
basis. Persons interested in attending
this meeting must register by March 10,
2015. For general questions about the
meeting, for assistance to register for the
meeting, to request an opportunity to
make an oral presentation, or to request
special accommodations due to a
disability, contact Laura Bradbard (see
Contact Person). Please include your
name, organization, and contact
information. If you are requesting an
VerDate Sep<11>2014
21:56 Feb 12, 2015
Jkt 235001
SUPPLEMENTARY INFORMATION:
I. Background
[FR Doc. 2015–02976 Filed 2–12–15; 8:45 am]
AGENCY:
opportunity to speak, please send a brief
summary of your comments. Early
registration for the meeting is
encouraged due to limited time and
space.
FDA considers the timely review of
the safety and effectiveness of new
animal drugs to be central to the
Agency’s mission to protect and
promote the public health. Before 2004,
the timeliness and predictability of the
new animal drug review program was a
concern. The Animal Drug User Fee Act
enacted in 2003 (Pub. L. 108–130;
hereinafter referred to as ‘‘ADUFA I’’),
authorized FDA to collect user fees for
5 years—fiscal year (FY) 2004 to FY
2008—that were to be dedicated to
expediting the review of new animal
drug applications according to certain
performance goals and to expand and
modernize the new animal drug review
program. The Agency agreed to meet a
comprehensive set of performance goals
established to show significant
improvement in the timeliness and
predictability of the new animal drug
review process. The implementation of
ADUFA I provided a significant funding
increase that enabled FDA to increase
the number of staff dedicated to the new
animal drug application review process.
In 2008, before ADUFA I expired,
Congress passed the Animal Drug User
Fee Amendments of 2008 (Pub. L. 110–
316; hereinafter referred to as ‘‘ADUFA
II’’), which included an extension of
ADUFA for an additional 5 years—FY
2009 to FY 2013. ADUFA II
performance goals were established
based on ADUFA I FY 2008 review
timeframes. In addition, FDA provided
program enhancements to reduce review
cycles and improve communications
during reviews.
In 2013, before ADUFA II expired,
Congress passed ADUFA III (Pub. L.
113–14), which was signed by the
President on June 13, 2013. Like its
predecessors, ADUFA III includes its
own comprehensive set of performance
goals. One such goal, as stated in the
ADUFA III goals letter, is: Beginning in
early FY 2014, the Agency agrees to
explore, in concert with industry, the
feasibility of pursuing statutory
revisions, consistent with the Agency’s
mission to protect and promote the
public health, that may expand the use
of conditional approvals to other
appropriate categories of new animal
drug applications and develop
recommendations by September 30,
2015.
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
8091
Currently, the conditional approval
provisions allow an applicant to market
a new animal drug intended for a minor
species or a minor use in a major
species after the applicant has
demonstrated that the drug is safe and
can be manufactured according to
standards applicable to approval of
applications under section 512(b)(1) of
the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 360b(b)(1)). FDA and
members of regulated industry jointly
agreed to explore, as part of the
performance goals outlined in the
ADUFA III goals letter, statutory
changes to expand the use of
conditional approval to other
appropriate categories of new animal
drugs.
This public meeting is intended to
provide an additional opportunity for
public comment. The Agency is
especially interested in receiving
comments during the meeting on the
categories of new animal drug
applications that would be considered
‘‘appropriate’’ and why; concerns, if
any, that might arise due to the
expansion of the Conditional Approval
process; and the length of marketing
exclusivity, if any, that should be
associated with the expansion of the
Conditional Approval process.
FDA will consider comments received
at this meeting as it moves forward with
this process.
FDA has already opened public
docket FDA Docket No. FDA–2014–N–
1049 to receive comments on the issue
(79 FR 53430, September 9, 2014).
Although you can comment on this
document at any time, to ensure that the
Agency considers your comment before
finalizing work on the exploration
process described in this document,
submit either electronic or written
comments by September 30, 2015.
II. Participation in a Public Meeting
While oral presentations from specific
individuals and organizations may be
limited due to time constraints during
the public meeting, stakeholders may
submit electronic or written comments
discussing any issues of concern to the
administration record (the docket). All
relevant data and documentation should
be submitted with the comments to
Docket No. FDA–2014–N–1049. Submit
electronic comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. It is only
necessary to send one set of comments.
Identify comments with the docket
number FDA–2014–N–1049. Received
comments may be seen in the Division
E:\FR\FM\13FEN1.SGM
13FEN1
Agencies
[Federal Register Volume 80, Number 30 (Friday, February 13, 2015)]
[Notices]
[Pages 8089-8091]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-02976]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-2187]
Identifying Potential Biomarkers for Qualification and Describing
Contexts of Use To Address Areas Important to Drug Development; Request
for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is seeking
information to facilitate development and qualification of biomarkers
in areas related to human drug therapeutics. Towards this goal, FDA is
encouraging interested groups and individuals to submit information on
specific medical and biological areas where novel biomarkers can be
identified that would meaningfully advance drug development. FDA
encourages respondents to describe evidentiary considerations that are
important to qualify these biomarkers for a specific context of use.
Details of information that should be provided to the Agency are
described in the survey.
DATES: Submit either electronic or written comments by April 14, 2015.
ADDRESSES: You may submit comments by any of the following methods:
Electronic Submissions
Submit electronic comments in either of the following ways:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
SurveyMonkey Link: https://www.surveymonkey.com/s/RHJLHS7.
This survey may be used to provide feedback on answers to questions
regarding potential biomarkers for qualification and to describe
contexts of use to address areas important to drug development.
Written Submissions
Submit written submissions in the following ways:
Mail/Hand delivery/Courier (for paper submissions):
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Instructions: All submissions received must include the Docket No.
FDA-2014-N-2187 for this document. All comments received may be posted
without change to https://www.regulations.gov, including any personal
information provided. It is only necessary to send one set of comments.
For additional information on submitting comments, see the ``Request
for Information'' heading of the SUPPLEMENTARY INFORMATION section of
this document.
Docket: For access to the docket to read background documents or
comments received, go to https://www.regulations.gov and insert the
docket number, found in brackets in the heading of this document, into
the ``Search'' box and follow the prompts and/or go to the Division of
Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852,
between 9 a.m. and 4 p.m., Monday through Friday.
FOR FURTHER INFORMATION CONTACT: Marianne Noone, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 21, Rm. 4528, Silver Spring, MD 20993-0002, 301-796-7495.
[[Page 8090]]
SUPPLEMENTARY INFORMATION:
I. Background
The President signed into law the Food and Drug Administration
Safety and Innovation Act (FDASIA) (Pub. L. 112-144) on July 9, 2012.
Title I of FDASIA reauthorizes the Prescription Drug User Fee Act
(PDUFA) and provides FDA with the user fee resources necessary to
maintain an efficient review process for human drug and biological
products. The reauthorization of PDUFA added performance goals and
procedures for the Agency that represent FDA's commitments during
fiscal years 2013 through 2017. These commitments are fully described
in the document entitled ``PDUFA Reauthorization Performance Goals and
Procedures Fiscal Years 2013 through 2017'' (PDUFA Goals Letter),
available on FDA's Web site at https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf. Section IX
of the PDUFA Goals Letter entitled ``Enhancing Regulatory Science and
Expediting Drug Development'' references support for the identification
and advancement of biomarkers.
A biomarker is an objective characteristic that is measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to treatment. Biomarkers can
serve many purposes in clinical drug development, including the
following: Defining the appropriate patient populations for study, as
well as those who should receive the drug in clinical practice;
pharmacodynamic markers for proof of concept and dose selection; and
pharmacodynamic markers of adverse effects. A subset of pharmacodynamic
biomarkers can serve as replacements for clinical efficacy endpoints
that reflect how a patient feels, functions, or survives. The path to
development of promising therapeutics can be enabled by the
availability of biomarkers that are analytically validated and
clinically qualified for a specific context of use (i.e., a
comprehensive, clear, and precise statement that describes the manner
of use, interpretation, and purpose of use of a biomarker in drug
development).
Qualification is based on a body of evidence that demonstrates that
the biomarkers are fit for purpose in drug development and evaluation
(https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm). Further,
qualification is dependent on the specific proposed context of use.
Biomarkers that are qualified can help to progressively reduce
uncertainty about the outcome of clinical development programs.
Public/private partnerships involving regulatory, academic, and
industry scientists, collaborating within a precompetitive framework,
are essential to catalyzing progress. Because of limitations in
resources, such efforts must be focused on the opportunities that offer
the greatest potential for impact.
FDA intends to facilitate identification of the most promising
biomarkers and the areas important to drug development and to promote
efforts that will aid in the qualification and regulatory adoption of
the drug development framework.
II. Request for Information
FDA is seeking public feedback to identify promising biomarker
candidates in areas important to drug development and to identify
considerations for evidence needed to qualify various types of
biomarkers for specific contexts of use. FDA requests identification of
specific biomarkers with a proposed context of use and of the type of
evidence needed to support qualification. After reviewing the
information provided, FDA will post the collated information on its Web
site.
A. Information Requirements
In general, submitted information should include the following for
each biomarker nominated, as well as any other relevant information:
Areas that have a critical need for biomarkers to assist
drug development;
The name of the biomarker;
The proposed context of use for the biomarker (if known);
The reason why the biomarker should be considered, taking
into account its usefulness as a drug development tool; and
Any evidence that should be developed to support
qualification of the biomarker.
B. Questions and Requests
Specific questions and requests are as follows:
1. Are there specific aspects of drug development that could be
enhanced through the development of biomarkers?
a. Please list the specific applications of biomarkers that address
areas important to drug development.
b. Please list the specific areas (for example, a specific disease
area or an organ toxicity) needed for development of biomarkers
important to drug development.
c. Is there information or efforts which could be leveraged to
advance these areas? If yes, please describe.
d. Are there areas that appear to be promising for the development
of new biomarkers and for which collaborative engagement from
stakeholders offers a path forward? If so, please explain.
Are there groups positioned to accomplish this? If yes,
please describe.
e. Are there barriers that preclude engagement or investment in
biomarkers for these priority areas? If yes, please explain.
2. In each of these priority areas that are important to drug
development, please provide the following information:
a. Biomarker: What specific biomarkers do you believe represent the
greatest near-term opportunity to establish utility in drug development
(i.e., that could be substantially advanced by facilitating discussion
and consensus building)?
b. Rationale: Why should the biomarker(s) be included on the list,
taking into account its usefulness in regulatory decisionmaking as a
drug development tool?
c. Context of use: Can you please describe/propose a specific
context of use for the biomarker(s)?
d. Evidentiary gaps: To support the proposed context of use, what
do you see as the largest evidentiary gaps that need to be addressed to
permit ``fit for purpose'' qualification?
e. How can these evidentiary gaps be addressed?
f. Collaborative data sharing: Can any of these gaps be addressed
by collaborative data sharing of existing data versus prospective
studies specifically dedicated to addressing the gap?
3. Please indicate your affiliation from the following list:
Academia, pharmaceutical sector, biotechnology sector, government,
professional organization, non-profit organization, clinician, patient
advocacy group, patient, or other (please provide specifics, if you
choose other).
III. Paperwork Reduction Act
This Federal Register notice requests input from biomarker experts
from academia, the pharmaceutical industry, and government
organizations on the evidentiary standards for biomarkers or on the
expectations about data for qualification of different types of
biomarkers.
This request is exempt from the Office of Management and Budget's
review under 5 CFR 1320.3(h)(4): Facts or opinions submitted in
response to general solicitations of comments from the public,
published in the Federal Register or other publications, regardless of
the form or format thereof,
[[Page 8091]]
provided that no person is required to supply specific information
pertaining to the commenter, other than that necessary for self-
identification, as a condition of the Agency's full consideration of
the comment.
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-02976 Filed 2-12-15; 8:45 am]
BILLING CODE 4164-01-P